News

Public · Published

Merck's Endometrial Cancer Drug Cuts Risk Of Death By 32% – FDA Decision Due By June 2027

Merck said its experimental drug Sacituzumab Tirumotecan helped patients with advanced or recurrent endometrial cancer live longer than chemotherapy. The Phase 3 trial showed a 32% lower risk of death, and the FDA accepted Merck's application for priority review with a decision due by June 15, 2027.

Published:

Updated:

What happened

Merck said its experimental drug Sacituzumab Tirumotecan helped patients with advanced or recurrent endometrial cancer live longer than chemotherapy. The Phase 3 trial showed a 32% lower risk of death, and the FDA accepted Merck's application for priority review with a decision due by June 15, 2027.

Confirmed

Global impact / market context

If approved, the drug could give Merck a new cancer treatment for patients whose disease worsened after prior therapy, adding potential future revenue. The 32% lower risk of death is a meaningful survival benefit, but approval is not guaranteed and the decision is still years away, so investors must weigh promise against delay.

Analyst inference

Merck shares traded 3% lower and were heading for a third straight session of losses, suggesting investors were not cheered by the trial news. That weak reaction may reflect concerns about how much the drug can add to sales or about competition from other treatments.

Analyst inference

What to watch

  1. The FDA set June 15, 2027 as its PDUFA date, which is the deadline for deciding on Merck's application. Investors should note that any approval and launch would come after that date. Confirmed
  2. Merck could seek additional regulatory approvals outside the United States and test the drug in earlier stages of endometrial cancer, which would widen the number of patients who might receive it. Proposed
  3. Watch whether Merck's shares keep falling after the 3% drop, since a continued decline could signal that investors doubt the drug's commercial value despite the survival benefit. Analyst inference

Evidence